Información del producto
PF-06263276 is a modulator that binds to the ATP binding site of the tyrosine kinase and inhibits its activity. It has been shown to be effective in treating inflammatory bowel disease in clinical studies. PF-06263276 is being developed as an alternative to baricitinib, which is currently undergoing clinical trials for treatment of rheumatoid arthritis. The mechanism of PF-06263276 has not been fully elucidated, but it has been hypothesized that it may work by preventing the activation of cells that are involved in inflammatory responses. This drug also prevents the synthesis of proinflammatory cytokines and chemokines and decreases the production of reactive oxygen species (ROS) from neutrophils.
Propiedades químicas
Consulta técnica sobre: 3D-WGC50262 PF-06263276
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
